Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968368 · ClinicalTrials.gov registry record · Phase 3
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
A Phase 3 study, sponsored by Shield Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT02968368: Completed Phase 3 study, sponsored by Shield Therapeutics.
NCT02968368 is a Phase 3 study that has completed, run by Shield Therapeutics. The registered enrollment target is 167 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968368, a Phase 3 study, has completed, sponsored by Shield Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
Primary Outcome
Change in hemoglobin concentration from baseline to Week 16.
Interventions
- OTHER Placebo
- DRUG Ferric maltol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2018-10-10 |
| Phase | Phase 3 |
What the finished NCT02968368 record still lists
NCT02968368 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02968368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02968368 about?
NCT02968368 is a clinical study titled "Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease". To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
What is the current status of trial NCT02968368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2016-12-01. Estimated completion is 2018-10-10.
What interventions are being tested in trial NCT02968368?
The interventions under investigation include: Placebo (OTHER), Ferric maltol (DRUG).
Who is sponsoring clinical trial NCT02968368?
This trial is sponsored by Shield Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02968368's enrollment target sits among peer trials
167 1463rd of 2000 higher than 538 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI